4.6 Article

Circulating platelet-derived extracellular vesicles are decreased after remote ischemic preconditioning in patients with coronary disease: A randomized controlled trial

期刊

JOURNAL OF THROMBOSIS AND HAEMOSTASIS
卷 19, 期 10, 页码 2605-2611

出版社

WILEY
DOI: 10.1111/jth.15441

关键词

blood coagulation; coronary artery disease; extracellular vesicles; fibrinolysis; ischemic preconditioning

资金

  1. Haemostasis Society of Australia and New Zealand
  2. National Health and Medical Research Council [1094384]
  3. National Health and Medical Research Council of Australia [1094384] Funding Source: NHMRC

向作者/读者索取更多资源

Remote ischemic preconditioning was found to decrease circulating levels of platelet-derived EVs in patients with coronary disease on antiplatelet therapy. This effect may be due to increased clearance/uptake of EVs or changes in production. Clinical variables could modify the effectiveness of RIPC.
Background Brief nonharmful ischemia, remote ischemic preconditioning (RIPC) has been proposed to confer benefit to patients with coronary artery disease via unknown mechanisms. Objectives We aimed to investigate the effect of RIPC on circulating levels of extracellular vesicles (EVs) and global coagulation and fibrinolytic factors in patients with coronary disease. Patients/Methods Blood samples were taken from 60 patients presenting for coronary angiography enrolled in a randomized, controlled trial before and after RIPC (3 x 5 min administration of 200 mmHg sphygmomanometer on the arm, n = 31) or sham (n = 29) treatment. Most patients (n = 48) had significant coronary artery disease and all were taking at least one antiplatelet agent. Results Remote ischemic preconditioning significantly decreased circulating levels of EVs expressing platelet markers CD41 and CD61 detected by flow cytometry in plasma, whereas no such effect was found on EVs expressing phosphatidylserine, CD62P, CD45, CD11b, CD144, CD31(+)/CD41(-), or CD235a. RIPC had no effect on the overall hemostatic potential assay or circulating antigen levels of tissue plasminogen activator, urokinase, plasminogen activator inhibitor-1, or plasminogen. Sham treatment had no effect on any studied parameter. Statin use inhibited the effect of RIPC on CD61(+) EVs, diabetes modified the effect of RIPC on CD45(+) and CD11b(+) EVs, and hypertension modified the effect of RIPC on CD235a(+) EVs. Conclusions Remote ischemic preconditioning decreased circulating levels of platelet-derived EVs in patients with coronary disease taking conventional antiplatelet therapy. This may reflect increased EV clearance/uptake or change in production. Clinical variables may alter the effectiveness of RIPC.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据